MétaCan
Menu
Back to cohort
Record W4415676376 · doi:10.1056/nejmsa2514268

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026

2025· article· en· W4415676376 on OpenAlexaff
Jake Scott, Michael S. Abers, Harleen Marwah, Nicole C. McCann, Eric A. Meyerowitz, Aaron Richterman, Derek Fleming, Leah E. Moat, Sydney G. Redepenning, Emily Smith, Maria E. Sundaram, Angela K. Ulrich, Christopher Alba, Cory Anderson, Meredith Arpey, Ethan D. Borre, Joseph Ladines-Lim, Angela J Mehr, Katherine M. Rich, Corey D. Watts, Nicole E. Basta, Jana Jarolimova, Rochelle P. Walensky, Caitlin M. Dugdale

Bibliographic record

VenueNew England Journal of Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsInfectious disease (medical specialty)PandemicVaccinationLive attenuated influenza vaccineDiseaseMEDLINEPublic health

Abstract

fetched live from OpenAlex

BACKGROUND: Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025-2026 season. METHODS: We conducted a systematic review of U.S.-licensed immunizations against coronavirus disease 2019 (Covid-19), respiratory syncytial virus (RSV), and influenza. We searched databases on PubMed/MEDLINE, Embase, and Web of Science for updates of the most recent review by the Advisory Committee on Immunization Practices (ACIP) Evidence-to-Recommendations for each disease, which was performed during the 2023-2024 period. Outcomes included vaccine efficacy and effectiveness against hospitalization, other clinical end points, and safety. RESULTS: Of 17,263 identified references, 511 studies met the inclusion criteria. Covid-19 mRNA vaccines against the XBB.1.5 subvariant had pooled vaccine effectiveness against hospitalization of 46% (95% confidence interval [CI], 34 to 55; from cohort studies) and 50% (95% CI, 43 to 57; from case-control studies) among adults and 37% (95% CI, 29 to 44) among immunocompromised adults. In a case-control study, vaccines against the KP.2 subvariant showed an effectiveness of 68% (95% CI, 42 to 82). Maternal RSV vaccination (for infant protection), nirsevimab for infants, and RSV vaccines in adults who were 60 years of age or older showed vaccine effectiveness of 68% or more against hospitalization. Influenza vaccination had a pooled vaccine effectiveness of 48% (95% CI, 39 to 55) in adults between the ages of 18 and 64 years and 67% (95% CI, 58 to 75) in children against hospitalization. Safety profiles were consistent with previous evaluations. The diagnosis of myocarditis associated with Covid-19 vaccines occurred at rates of 1.3 to 3.1 per 100,000 doses in male adolescents, with lower risk associated with longer dosing intervals. The RSVpreF vaccine was associated with 18.2 excess cases of Guillain-Barré syndrome per million doses in older adults; a significant association with preterm birth was not observed when the vaccine was administered at 32 to 36 weeks' gestation. CONCLUSIONS: Ongoing peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025-2026 season. (Funded by the Center for Infectious Disease Research and Policy and the Alumbra Innovations Foundation.).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.016
metaresearch head score (Gemma)0.053
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.086

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0160.053
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0060.011
Bibliometrics0.0140.008
Science and technology studies0.0000.001
Scholarly communication0.0040.003
Open science0.0020.002
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.187
GPT teacher head0.499
Teacher spread0.311 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations49
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNew England Journal of MedicineSame topicRespiratory viral infections researchFrench-language works237,207